title: Management of the pregnant inflammatory bowel disease patient on anti-tumour necrosis factor: state of the art and future directions.
abstract: Antitumour necrosis factor (anti-TNF) therapy has been a major advance in the treatment of inflammatory bowel disease (IBD) by improving rates of mucosal healing, steroid-free remission, and decreasing rates of hospitalization and surgery. Because IBD affects women in their reproductive years, clinicians have and will continue to be asked in the future about the safety profile of these agents and their potential impact on pregnancy, the developing fetus and newborn. Immunoglobulin G transfer from the mother to fetus begins in the second trimester, with an elevation starting at 22 weeks of gestation and the largest amount transferred in the third trimester. Although research investigating the long-term outcomes of children exposed to anti-TNF therapy in utero is limited, there is no known adverse effect on either pregnancy or newborn outcomes including infectious complications with this class of drugs. The World Congress of Gastroenterology consensus statement on biological therapy for IBD considered infliximab and adalimumab to be low risk and compatible with use during conception and during pregnancy in at least the first two trimesters. Based on a clinical algorithm used at the University of Calgary Pregnancy and IBD clinic (Calgary, Alberta), recommendations have been provided on the management of pregnant patients on anti-TNF therapy, particularly with regard to third-trimester dosing, taking into account disease characteristics of individual patients. When educated about the safety of anti-TNF therapy during pregnancy, patients often choose to continue on therapy during the third trimester.
authors.forename: Yvette
authors.initials: Y
authors.lastname: Leung
authors.forename: Remo
authors.initials: R
authors.lastname: Panaccione
authors.forename: Subrata
authors.initials: S
authors.lastname: Ghosh
authors.forename: Cynthia H
authors.initials: CH
authors.lastname: Seow
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D002170:Canada; D003226:Congresses as Topic; D019317:Evidence-Based Medicine; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab
references.citation: Joint Bone Spine. 2009 Jan;76(1):28-34
references.pmid: 19059799
references.citation: Am J Gastroenterol. 2013 Sep;108(9):1426-38
references.pmid: 23752881
references.citation: J Rheumatol. 2009 Mar;36(3):635-41
references.pmid: 19132789
references.citation: Inflamm Bowel Dis. 2010 May;16(5):881-95
references.pmid: 19885906
references.citation: Clin Gastroenterol Hepatol. 2013 Mar;11(3):286-92; quiz e24
references.pmid: 23200982
references.citation: Ann Rheum Dis. 2011 May;70(5):823-6
references.pmid: 21362710
references.citation: Inflamm Bowel Dis. 2014 Mar;20(3):495-501
references.pmid: 24407486
references.citation: Dermatology. 2010;220(1):71-6
references.pmid: 19940453
references.citation: Am J Gastroenterol. 2013 Mar;108(3):433-40
references.pmid: 23318480
references.citation: Gastroenterology. 2009 Nov;137(5):1628-40
references.pmid: 19664627
references.citation: Aliment Pharmacol Ther. 2011 May;33(9):1053-8
references.pmid: 21366638
references.citation: Am J Gastroenterol. 2004 Dec;99(12):2385-92
references.pmid: 15571587
references.citation: Pediatr Infect Dis J. 2010 Sep;29(9):801-5
references.pmid: 20803841
references.citation: Clin Dev Immunol. 2012;2012:985646
references.pmid: 22235228
references.citation: Aliment Pharmacol Ther. 2013 Sep;38(5):501-12
references.pmid: 23855425
references.citation: Am J Gastroenterol. 2012 Sep;107(9):1409-22
references.pmid: 22890223
references.citation: Rev Reprod. 1999 May;4(2):81-9
references.pmid: 10357095
references.citation: Am J Gastroenterol. 2011 Apr;106(4):559-62
references.pmid: 21468063
references.citation: Inflamm Bowel Dis. 2011 Sep;17(9):1846-54
references.pmid: 21830263
references.citation: J Crohns Colitis. 2010 Nov;4(5):603-5
references.pmid: 21122568
references.citation: N Engl J Med. 2003 Feb 13;348(7):601-8
references.pmid: 12584368
references.citation: J Crohns Colitis. 2010 Feb;4(1):63-101
references.pmid: 21122490
references.citation: Aliment Pharmacol Ther. 2013 Jul;38(1):38-43
references.pmid: 23675854
references.citation: Int Immunol. 2001 Aug;13(8):993-1002
references.pmid: 11470769
references.citation: Am J Gastroenterol. 2011 Feb;106(2):214-23; quiz 224
references.pmid: 21157441
references.citation: Clin Gastroenterol Hepatol. 2006 Oct;4(10):1255-8
references.pmid: 17045211
references.citation: Am J Gastroenterol. 2008 May;103(5):1203-9
references.pmid: 18422816
references.citation: Am J Reprod Immunol. 1996 Nov;36(5):248-55
references.pmid: 8955500
references.citation: Gut. 2011 Feb;60(2):198-203
references.pmid: 21115547
references.citation: Clin Gastroenterol Hepatol. 2013 Mar;11(3):318-21
references.pmid: 23103819
references.citation: BMC Med. 2013 Jul 31;11:174
references.pmid: 23902720